1,396 Shares in CVS Health Co. (NYSE:CVS) Bought by Murphy & Mullick Capital Management Corp

Murphy & Mullick Capital Management Corp purchased a new position in CVS Health Co. (NYSE:CVS) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 1,396 shares of the pharmacy operator’s stock, valued at approximately $63,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Zions Bancorporation N.A. boosted its holdings in shares of CVS Health by 17.4% during the 4th quarter. Zions Bancorporation N.A. now owns 4,944 shares of the pharmacy operator’s stock valued at $222,000 after purchasing an additional 732 shares during the last quarter. Segall Bryant & Hamill LLC boosted its stake in CVS Health by 4.3% during the fourth quarter. Segall Bryant & Hamill LLC now owns 30,641 shares of the pharmacy operator’s stock valued at $1,375,000 after buying an additional 1,269 shares during the last quarter. Angeles Investment Advisors LLC grew its holdings in CVS Health by 3.7% during the 4th quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator’s stock valued at $256,000 after buying an additional 204 shares in the last quarter. Mountain Hill Investment Partners Corp. bought a new stake in CVS Health in the 4th quarter worth approximately $3,350,000. Finally, Drexel Morgan & Co. raised its holdings in shares of CVS Health by 199.8% during the 4th quarter. Drexel Morgan & Co. now owns 600,165 shares of the pharmacy operator’s stock worth $26,941,000 after acquiring an additional 400,000 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

CVS Health Stock Up 0.6 %

Shares of CVS Health stock opened at $67.59 on Friday. CVS Health Co. has a 1 year low of $43.56 and a 1 year high of $80.75. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. The stock has a market cap of $85.22 billion, a price-to-earnings ratio of 18.47, a PEG ratio of 0.98 and a beta of 0.54. The firm’s 50-day moving average is $61.83 and its two-hundred day moving average is $57.60.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. As a group, research analysts expect that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.94%. The ex-dividend date is Tuesday, April 22nd. CVS Health’s payout ratio is currently 72.68%.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Michael F. Mahoney purchased 30,000 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was bought at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the purchase, the director now owns 39,356 shares in the company, valued at $2,625,045.20. This represents a 320.65 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP James David Clark sold 7,513 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the sale, the senior vice president now owns 8,394 shares in the company, valued at $556,941.90. The trade was a 47.23 % decrease in their position. The disclosure for this sale can be found here. 0.24% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Evercore ISI increased their price objective on shares of CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Monday, January 27th. Leerink Partners upgraded CVS Health from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $55.00 to $75.00 in a research report on Thursday, February 13th. UBS Group lowered their price objective on CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a research note on Tuesday, February 11th. Argus set a $77.00 target price on CVS Health in a research report on Tuesday, February 18th. Finally, Wolfe Research raised their price target on CVS Health from 67.00 to 70.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $70.39.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.